Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy

PURPOSE: The aim of this study was to investigate whether 11q loss of heterozygosity (LOH) aberration would impact the response of the primary tumor to neoadjuvant chemotherapy or to the degree of surgical resection in neuroblastoma (NB) patients with MYCN amplification. METHODS: The clinical data o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xian-Ying, Qu, Li-Jun, Duan, Xian-Lun, Zuo, Wei, Sai, Kai, Rui, Gang, Gong, Xian-Feng, Ding, Yi-bo, Gao, Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226623/
https://www.ncbi.nlm.nih.gov/pubmed/35757140
http://dx.doi.org/10.3389/fped.2022.898918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226623/
https://www.ncbi.nlm.nih.gov/pubmed/35757140
http://dx.doi.org/10.3389/fped.2022.898918

Ejemplares similares